ARPA-H Invests $125M in On-Demand RNA Medicine Manufacturing; ArsenalBio Pivots to In Vivo CAR T Cell Therapies for Solid Tumors

September 6, 2026

The Pharma Letter USA

Overview

ARPA-H has committed $125 million to five teams developing on-demand manufacturing capabilities for RNA medicines, a strategic investment to enhance rapid pharmaceutical response to future public health crises. Simultaneously, ArsenalBio announced a strategic pivot, discontinuing its ex vivo solid tumor cell therapy programs to concentrate on the more accessible and efficient in vivo CAR T cell therapies. Intellia Therapeutics continues to advance its Lonvo-z and Nex-z programs, though recent clinical data updates for these assets were published prior to April.

In Depth

Key Findings

The Advanced Research Projects Agency for Health (ARPA-H) has allocated a substantial $125 million to five distinct teams dedicated to developing on-demand manufacturing technologies for RNA medicines. This significant federal investment aims to establish resilient and rapid pharmaceutical production capabilities for future health crises. In parallel, ArsenalBio, a prominent cell therapy company, has announced a strategic shift, discontinuing its existing solid tumor cell therapy programs to pivot towards the development of in vivo CAR T cell therapies. This pivot reflects a broader industry trend towards more efficient and scalable therapeutic delivery. Meanwhile, Intellia Therapeutics continues to progress its pipeline, specifically mentioning Lonvo-z and Nex-z, though more detailed clinical updates for these gene-editing assets were predominantly released earlier in the year.

Technical / Clinical Details

The ARPA-H initiative focuses on creating modular, automated, and rapidly deployable platforms for RNA medicine synthesis, including vaccines and therapeutics. This aims to dramatically reduce lead times from discovery to deployment, potentially lowering manufacturing costs and increasing flexibility in response to emergent needs. The program’s success could establish a blueprint for future biomanufacturing paradigms, minimizing reliance on centralized, large-scale facilities. ArsenalBio’s strategic redirection towards in vivo CAR T cell therapies acknowledges the inherent complexities, high costs, and logistical challenges associated with traditional ex vivo cell manufacturing. By engineering CAR T cells directly within the patient’s body, this approach seeks to simplify the therapeutic process, expand patient accessibility, and potentially reduce the incidence of manufacturing failures. This shift could significantly impact the scalability of CAR T cell therapies, particularly for large indications like solid tumors. Intellia Therapeutics’ Lonvo-z and Nex-z represent cutting-edge CRISPR-Cas9 gene editing treatments targeting specific genetic disorders. These in vivo gene-editing candidates aim to provide a permanent correction to the root cause of diseases by precisely modifying genomic DNA within the patient’s cells, leveraging the precision of CRISPR technology to offer potentially curative solutions.

Background & Context

The COVID-19 pandemic underscored critical vulnerabilities in global pharmaceutical supply chains and highlighted the urgent need for agile manufacturing platforms. ARPA-H’s investment directly addresses these lessons, positioning the US at the forefront of rapid RNA therapeutic production as a matter of national security and public health preparedness. Within the cell therapy sector, the move towards in vivo CAR T therapies by companies like ArsenalBio is a natural evolution, building upon the successes and limitations of first-generation ex vivo CAR T products. While ex vivo therapies have achieved remarkable efficacy in hematologic malignancies, their manufacturing bottlenecks hinder widespread adoption. In vivo approaches promise to overcome these hurdles, offering a more patient-friendly and scalable solution. Gene-editing companies, including Intellia, are consistently working to demonstrate the long-term safety and durability of their in vivo therapies. The market is increasingly demanding not just efficacy but also an acceptable safety profile and the ability to scale production for broader clinical utility.

Strategic Significance & Outlook

ARPA-H’s substantial investment in RNA manufacturing is set to accelerate innovation across the RNA therapeutic landscape, enhancing global preparedness for future pandemics and ensuring more robust access to cutting-edge medicines. This initiative could catalyze the development of entirely new classes of RNA-based treatments. ArsenalBio’s strategic pivot to in vivo CAR T cell therapies signals a significant trend in the immuno-oncology space, potentially leading to more cost-effective and accessible cell therapy options for solid tumors, a field where current treatments often face significant limitations. For Intellia Therapeutics, continued progress with Lonvo-z and Nex-z will be crucial in demonstrating the full potential of in vivo gene editing to provide permanent cures for previously untreatable genetic diseases. The confluence of these developments paints a picture of a regenerative medicine field rapidly maturing, driven by technological innovation, strategic funding, and a relentless pursuit of scalable and accessible therapeutic solutions.

Source: https://www.thepharmaletter.com/ones-to-watch/intellia-therapeutics

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.